The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis
出版年份 2021 全文链接
标题
The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 22, Issue 13, Pages 859-879
出版商
Future Medicine Ltd
发表日期
2021-08-20
DOI
10.2217/pgs-2020-0127
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
- (2019) Jeerayuth Auttajaroon et al. HELICOBACTER
- Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection
- (2018) M. Zamani et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial
- (2018) Ping-I Hsu et al. Clinical Gastroenterology and Hepatology
- Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
- (2018) Haruhiko Ozaki et al. DIGESTION
- Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
- (2018) Nihal El Rouby et al. Expert Opinion on Drug Metabolism & Toxicology
- Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
- (2018) Wen Zhong Liu et al. HELICOBACTER
- Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
- (2018) Young Woon Chang et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients
- (2018) Yi Song et al. Biomed Research International
- CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
- (2018) Tsung-Jung Lin et al. World Journal of Clinical Cases
- Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
- (2017) James K.Y. Hooi et al. GASTROENTEROLOGY
- Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens
- (2017) Tadashi Shimoyama et al. INTERNAL MEDICINE
- Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori
- (2017) Yun-An Lin et al. MEDICAL SCIENCE MONITOR
- Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
- (2016) Kittichet Phiphatpatthamaamphan et al. Asian Pacific Journal of Cancer Prevention
- Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy
- (2016) Zhiqiang Song et al. DIGESTIVE AND LIVER DISEASE
- Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia
- (2016) D.D. Nabinger et al. GENETICS AND MOLECULAR RESEARCH
- Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication
- (2016) Burhan OZDIL et al. Turkish Journal of Gastroenterology
- CYP2C19 polymorphism influencesHelicobacter pylorieradication
- (2016) Chao-Hung Kuo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Tailored versus Triple plus Bismuth or Concomitant Therapy as InitialHelicobacter pyloriTreatment: A Randomized Trial
- (2015) Liya Zhou et al. HELICOBACTER
- Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective
- (2015) Muhammad Miftahussurur et al. MOLECULES
- First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype
- (2015) Yoshimasa Saito WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion
- (2014) Mitsushige Sugimoto et al. HELICOBACTER
- Helicobacter pylorieradication for preventing gastric cancer
- (2014) Bin Lu WORLD JOURNAL OF GASTROENTEROLOGY
- Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials
- (2014) A. C. Ford et al. BMJ-British Medical Journal
- Proton Pump Inhibitors in Pediatrics
- (2013) Robert M. Ward et al. PEDIATRIC DRUGS
- The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments
- (2012) Dolores Serrano et al. CURRENT DRUG METABOLISM
- The benefit of mass eradication ofHelicobacter pyloriinfection: a community-based study of gastric cancer prevention
- (2012) Yi-Chia Lee et al. GUT
- Helicobacter pylori Infection
- (2011) Deng-Chyang Wu et al. MEDICINE
- Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults
- (2010) Xiaolin Pan et al. CLINICAL THERAPEUTICS
- Evidencias e incertidumbres del uso clínico de los inhibidores de la bomba de protones
- (2010) Carlos Martín de Argila de Prados Gastroenterologia y Hepatologia
- The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole
- (2010) Jeong Hoon Lee et al. Gut and Liver
- The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people
- (2010) L. Zhang et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects
- (2010) V. W. Y. Lee et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
- (2009) N. G. HUNFELD et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis
- (2008) Fujun Zhao et al. HELICOBACTER
- Effect of the CYP2C19 polymorphism on the eradication rate ofHelicobacter pyloriinfection by 7-day triple therapy with regular proton pump inhibitor dosage
- (2008) Jung Mook Kang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- New concepts of resistance in the treatment of Helicobacter pylori infections
- (2008) David Y Graham et al. Nature clinical practice. Gastroenterology & hepatology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search